Maprotiline Ratiopharm (Maprotiline Hydrochloride)

Maprotiline is a tetracyclic antidepressant that acts on depressive disorders.

• Major depressive disorder: reduction of depressive symptoms and improvement of mood.
• Depressive episodes in bipolar disorder (adjunct therapy): alleviation of depressive phase symptoms.
• Dysthymic disorder: long‑term improvement of persistent low mood.

• Maprotiline inhibits the reuptake of norepinephrine by blocking the norepinephrine transporter, leading to increased synaptic concentrations of norepinephrine. This selective norepinephrine reuptake inhibition enhances noradrenergic neurotransmission, which contributes to its antidepressant effects. The drug has minimal impact on serotonin and dopamine pathways.

Common side effects are usually mild to moderate and may resolve with continued therapy.

Common Side Effects

• Dry mouth: reduced salivation causing discomfort.
• Drowsiness: increased sleepiness or fatigue.
• Constipation: slowed gastrointestinal motility.
• Weight gain: gradual increase in body weight.
• Dizziness: sensation of light‑headedness.
• Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

• Seizures: risk of convulsive episodes.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Agranulocytosis: dangerously low white blood cell count.
• Suicidal thoughts: emergence or worsening of suicidal ideation.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

• Cardiovascular assessment: monitor blood pressure and heart rhythm in patients with cardiac disease.
• Discontinuation syndrome: avoid abrupt cessation; taper dose under medical supervision.
• Elderly patients: start at lower doses and monitor for increased sensitivity.
• Hepatic function: assess liver enzymes before and during treatment.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Maprotiline may interact with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome.
• Other tricyclic antidepressants: additive cardiotoxicity.
• CNS depressants (e.g., benzodiazepines): enhanced sedation.
• Linezolid: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: possible additive blood pressure lowering.
• Anticholinergic drugs: heightened anticholinergic burden.
• Alcohol: increased drowsiness and CNS depression.
• CYP2D6 inhibitors: elevated maprotiline plasma levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding.